JP2003521930A - 第ＶＩＩ因子または第ＶＩＩａ因子様分子 - Google Patents

第ＶＩＩ因子または第ＶＩＩａ因子様分子

Info

Publication number
JP2003521930A
JP2003521930A JP2001558082A JP2001558082A JP2003521930A JP 2003521930 A JP2003521930 A JP 2003521930A JP 2001558082 A JP2001558082 A JP 2001558082A JP 2001558082 A JP2001558082 A JP 2001558082A JP 2003521930 A JP2003521930 A JP 2003521930A
Authority
JP
Japan
Prior art keywords
conjugate
polypeptide
amino acid
group
substitution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001558082A
Other languages
English (en)
Japanese (ja)
Inventor
アンデルセン，キム・ヴィルブール
ぺダーセン，アンデルス・ヒェルホルト
ボルネス，クラウス
Original Assignee
マキシゲン・エイピーエス
マキシゲン・ホールディングス・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by マキシゲン・エイピーエス, マキシゲン・ホールディングス・リミテッド filed Critical マキシゲン・エイピーエス
Publication of JP2003521930A publication Critical patent/JP2003521930A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2001558082A 2000-02-11 2001-02-12 第ＶＩＩ因子または第ＶＩＩａ因子様分子 Pending JP2003521930A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DK200000218 2000-02-11
DKPA200000218 2000-02-11
DKPA200001558 2000-10-18
DK200001558 2000-10-18
PCT/DK2001/000094 WO2001058935A2 (en) 2000-02-11 2001-02-12 FACTOR VII OR VIIa-LIKE MOLECULES

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2005122294A Division JP4509846B2 (ja) 2000-02-11 2005-04-20 第ＶＩＩ因子または第ＶＩＩａ因子様分子

Publications (1)

Publication Number Publication Date
JP2003521930A true JP2003521930A (ja) 2003-07-22

Family

ID=26068765

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2001558082A Pending JP2003521930A (ja) 2000-02-11 2001-02-12 第ＶＩＩ因子または第ＶＩＩａ因子様分子
JP2005122294A Expired - Fee Related JP4509846B2 (ja) 2000-02-11 2005-04-20 第ＶＩＩ因子または第ＶＩＩａ因子様分子

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2005122294A Expired - Fee Related JP4509846B2 (ja) 2000-02-11 2005-04-20 第ＶＩＩ因子または第ＶＩＩａ因子様分子

Country Status (18)

Country Link
US (13) US6806063B2 (enExample)
EP (3) EP1982732A3 (enExample)
JP (2) JP2003521930A (enExample)
CN (1) CN100488562C (enExample)
AT (1) ATE428445T1 (enExample)
AU (3) AU783512B2 (enExample)
CA (2) CA2739933A1 (enExample)
CY (1) CY1109614T1 (enExample)
DE (1) DE60138364D1 (enExample)
DK (1) DK1257295T3 (enExample)
ES (1) ES2325877T3 (enExample)
IL (2) IL150692A0 (enExample)
NO (1) NO20023804L (enExample)
NZ (1) NZ521257A (enExample)
PL (2) PL204285B1 (enExample)
PT (1) PT1257295E (enExample)
RU (1) RU2278123C2 (enExample)
WO (1) WO2001058935A2 (enExample)

Cited By (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006513142A (ja) * 2002-06-21 2006-04-20 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト ペジル化されたｖｉｉ因子糖形体
JP2007504809A (ja) * 2003-09-09 2007-03-08 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 凝固因子ｖｉｉポリペプチド
JP2008507990A (ja) * 2004-08-02 2008-03-21 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト Ｆｖｉｉの抱合体
JP2009507508A (ja) * 2005-09-14 2009-02-26 ノボ ノルディスク ヘルス ケア アーゲー ヒト凝固第ｖｉｉ因子ポリペプチド
JP2009278980A (ja) * 2000-09-13 2009-12-03 Novo Nordisk Health Care Ag ヒト凝固因子ｖｉｉ変異型
JP2010514819A (ja) * 2007-01-03 2010-05-06 ノボ ノルディスク ヘルス ケア アーゲー 凝固第ｖｉｉ因子関連ポリペプチドの皮下投与
US8008252B2 (en) 2001-10-10 2011-08-30 Novo Nordisk A/S Factor VII: remodeling and glycoconjugation of Factor VII
JP2011167193A (ja) * 2003-09-09 2011-09-01 Novo Nordisk Health Care Ag 凝固因子ｖｉｉポリペプチド
JP2012095641A (ja) * 2003-03-20 2012-05-24 Bayer Healthcare Llc ＦＶＩＩおよびＦＶＩＩａの変種
US8716239B2 (en) 2001-10-10 2014-05-06 Novo Nordisk A/S Granulocyte colony stimulating factor: remodeling and glycoconjugation G-CSF
US8716240B2 (en) 2001-10-10 2014-05-06 Novo Nordisk A/S Erythropoietin: remodeling and glycoconjugation of erythropoietin
US8791066B2 (en) 2004-07-13 2014-07-29 Novo Nordisk A/S Branched PEG remodeling and glycosylation of glucagon-like peptide-1 [GLP-1]
US8841439B2 (en) 2005-11-03 2014-09-23 Novo Nordisk A/S Nucleotide sugar purification using membranes
US8853161B2 (en) 2003-04-09 2014-10-07 Novo Nordisk A/S Glycopegylation methods and proteins/peptides produced by the methods
US8911967B2 (en) 2005-08-19 2014-12-16 Novo Nordisk A/S One pot desialylation and glycopegylation of therapeutic peptides
US8916360B2 (en) 2003-11-24 2014-12-23 Novo Nordisk A/S Glycopegylated erythropoietin
US8969532B2 (en) 2006-10-03 2015-03-03 Novo Nordisk A/S Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography
US9005625B2 (en) 2003-07-25 2015-04-14 Novo Nordisk A/S Antibody toxin conjugates
JP2015512927A (ja) * 2012-04-16 2015-04-30 カンタブ バイオファーマシューティカルズ パテンツ リミテッド 最適化された皮下治療薬
US9029331B2 (en) 2005-01-10 2015-05-12 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
US9050304B2 (en) 2007-04-03 2015-06-09 Ratiopharm Gmbh Methods of treatment using glycopegylated G-CSF
US9150848B2 (en) 2008-02-27 2015-10-06 Novo Nordisk A/S Conjugated factor VIII molecules
US9187532B2 (en) 2006-07-21 2015-11-17 Novo Nordisk A/S Glycosylation of peptides via O-linked glycosylation sequences
US9187546B2 (en) 2005-04-08 2015-11-17 Novo Nordisk A/S Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
US9200049B2 (en) 2004-10-29 2015-12-01 Novo Nordisk A/S Remodeling and glycopegylation of fibroblast growth factor (FGF)
US9493499B2 (en) 2007-06-12 2016-11-15 Novo Nordisk A/S Process for the production of purified cytidinemonophosphate-sialic acid-polyalkylene oxide (CMP-SA-PEG) as modified nucleotide sugars via anion exchange chromatography

Families Citing this family (142)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7247708B2 (en) 1997-10-23 2007-07-24 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6747003B1 (en) * 1997-10-23 2004-06-08 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
EP1198565A1 (en) * 1999-07-07 2002-04-24 Maxygen Aps A method for preparing modified polypeptides
NZ521257A (en) * 2000-02-11 2004-10-29 Maxygen Aps Factor VII or VIIa-like molecules
US7220837B1 (en) 2000-04-28 2007-05-22 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7812132B2 (en) 2000-04-28 2010-10-12 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6905683B2 (en) * 2000-05-03 2005-06-14 Novo Nordisk Healthcare A/G Human coagulation factor VII variants
US7160540B2 (en) 2000-06-30 2007-01-09 Regents Of The University Of Minnesota Methods for detecting activity of clottings factors
US6423826B1 (en) * 2000-06-30 2002-07-23 Regents Of The University Of Minnesota High molecular weight derivatives of vitamin K-dependent polypeptides
US20030211094A1 (en) * 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
ES2429523T3 (es) * 2000-09-13 2013-11-15 Novo Nordisk Health Care Ag Variantes del factor VII de coagulación humana
US7173000B2 (en) 2000-11-09 2007-02-06 The Scripps Research Institute Modified factor VIIa
AU2002249096B2 (en) * 2001-03-22 2007-06-28 Novo Nordisk Health Care Ag Coagulation factor VII derivatives
US7235638B2 (en) * 2001-03-22 2007-06-26 Novo Nordisk Healthcare A/G Coagulation factor VII derivatives
US7052868B2 (en) * 2001-09-27 2006-05-30 Novo Nordisk Healthcare A/G Human coagulation factor VII polypeptides
WO2003027147A2 (en) * 2001-09-27 2003-04-03 Novo Nordisk Health Care Ag Human coagulation factor vii polypeptides
US7696163B2 (en) 2001-10-10 2010-04-13 Novo Nordisk A/S Erythropoietin: remodeling and glycoconjugation of erythropoietin
EP2305311A3 (en) * 2001-10-10 2011-07-20 BioGeneriX AG Glycoconjugation of peptides
US7795210B2 (en) 2001-10-10 2010-09-14 Novo Nordisk A/S Protein remodeling methods and proteins/peptides produced by the methods
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
US6960657B2 (en) * 2001-11-02 2005-11-01 Novo Nordisk Healthcare A/G Human coagulation factor VII polypeptides
JP2005512524A (ja) 2001-11-02 2005-05-12 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト ヒト凝固第ｖｉｉ因子ポリペプチド
US7125846B2 (en) 2001-11-09 2006-10-24 Novo Nordisk Healthcare A/G Pharmaceutical composition comprising factor VII polypeptides and factor V polypeptides
BR0215216A (pt) 2001-12-21 2004-11-16 Novo Nordisk Healthcare Ag Composição aquosa lìquida, método para preparar uma composição aquosa lìquida de um polipeptìdeo de fator vii, uso de uma composição aquosa lìquida, e, método para o tratamento de uma sìndrome de resposta ao fator vii
KR20040065278A (ko) * 2001-12-21 2004-07-21 노보 노르디스크 에이/에스 변경된 인자 ⅶ 폴리펩티드의 액체 조성물
US20060229239A9 (en) * 2002-03-08 2006-10-12 Mamoru Shoji Novel curcuminoid-factor VIIa constructs as suppressors of tumor growth and angiogenesis
US20050069551A1 (en) * 2002-03-08 2005-03-31 Emory University Cytotoxic compound-protein conjugates as suppressors of tumor growth and angiogenesis
WO2003093465A1 (en) * 2002-04-30 2003-11-13 Maxygen Holdings Ltd. FACTOR VII OR VIIa POLYPEPTIDE VARIANTS
US20040009918A1 (en) * 2002-05-03 2004-01-15 Hanne Nedergaard Stabilised solid compositions of modified factor VII
KR20050013148A (ko) 2002-06-21 2005-02-02 노보 노르디스크 에이/에스 인자 ⅶ 폴리펩티드의 안정화된 고체 조성물
DE60336555D1 (de) 2002-06-21 2011-05-12 Novo Nordisk Healthcare Ag Pegylierte glykoformen von faktor vii
DE60330923D1 (de) * 2002-09-25 2010-02-25 Novo Nordisk Healthcare Ag Menschliche Koagulationsfaktor VII Polypeptide
US6911323B2 (en) * 2002-09-25 2005-06-28 Novo Nordisk Healthcare A/G Human coagulation factor VII polypeptides
EP1549677B1 (en) * 2002-09-30 2011-04-13 Bayer HealthCare LLC FVII OR FVIIa VARIANTS HAVING INCREASED CLOTTING ACTIVITY
CA2519092C (en) 2003-03-14 2014-08-05 Neose Technologies, Inc. Branched water-soluble polymers and their conjugates
MXPA05009770A (es) 2003-03-18 2005-11-17 Novo Nordisk Healthcare Ag Metodo para la produccion de serina proteasas que contienen residuos de gla.
CA2518327A1 (en) * 2003-03-18 2004-09-30 Novo Nordisk Health Care Ag Liquid, aqueous, pharmaceutical compositions of factor vii polypeptides
US7897734B2 (en) * 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
WO2004091499A2 (en) 2003-04-09 2004-10-28 Neose Technologies, Inc. Intracellular formation of peptide conjugates
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
WO2006127896A2 (en) 2005-05-25 2006-11-30 Neose Technologies, Inc. Glycopegylated factor ix
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US7348004B2 (en) 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
EP3002012A1 (en) 2003-05-06 2016-04-06 Biogen Hemophilia Inc. Clotting factor-fc chimeric proteins to treat hemophilia
WO2004103275A2 (en) 2003-05-09 2004-12-02 Neose Technologies, Inc. Compositions and methods for the preparation of human growth hormone glycosylation mutants
CN1780638B (zh) * 2003-05-23 2010-04-14 诺和诺德医疗保健公司 氧化硅涂层玻璃作为容器内壁材料的用途及以该材料作内壁的容器
DK1644504T3 (da) * 2003-06-19 2010-05-25 Bayer Healthcare Llc Faktor VII- eller -VIIA-Gla-domænevarianter
WO2004112828A1 (en) 2003-06-25 2004-12-29 Novo Nordisk Health Care Ag Liquid composition of factor vii polypeptides
JP5306597B2 (ja) * 2003-07-01 2013-10-02 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 第ｖｉｉ因子ポリペプチドの液体水性薬学的組成物
WO2005025623A2 (en) * 2003-07-28 2005-03-24 Emory University Ef-24-factor vii conjugates
US20060198819A1 (en) * 2003-08-08 2006-09-07 Novo Nordisk Healthcare A/G Use of galactose oxidase for selective chemical conjugation of protractor molecules to proteins of therapeutic interest
JP2007501811A (ja) * 2003-08-08 2007-02-01 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 治療的な関心対象のタンパク質に対する遅延分子の選択的な化学物質接合のためのガラクトースオキシダーゼの使用。
JP5653572B2 (ja) 2003-08-14 2015-01-14 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 第ｖｉｉ因子ポリペプチドの液状水性医薬組成物
WO2005032581A2 (en) * 2003-10-07 2005-04-14 Novo Nordisk Health Care Ag Hybrid molecules having factor vii/viia activity
US8633157B2 (en) 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
ES2926359T3 (es) 2003-12-01 2022-10-25 Novo Nordisk Healthcare Ag Filtración de virus de composiciones líquidas del Factor VII
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
US7956032B2 (en) 2003-12-03 2011-06-07 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
ATE507822T1 (de) 2003-12-19 2011-05-15 Novo Nordisk Healthcare Ag Stabilisierte zusammensetzungen von faktor-vii- polypeptiden
US8361961B2 (en) 2004-01-08 2013-01-29 Biogenerix Ag O-linked glycosylation of peptides
EP1708755B1 (en) 2004-01-21 2012-03-21 Novo Nordisk Health Care AG Transglutaminase mediated conjugation of peptides
KR100545720B1 (ko) * 2004-05-31 2006-01-24 메덱스젠 주식회사 당화된 면역글로불린 및 이를 포함하는 면역접합체
US20080058255A1 (en) * 2004-06-21 2008-03-06 Novo Nordisk Healthcare A/G Glycosylation-Disrupted Factor VII Variants
WO2006018204A1 (en) * 2004-08-17 2006-02-23 Zlb Behring Gmbh Modified vitamin k dependent polypeptides
WO2006031811A2 (en) 2004-09-10 2006-03-23 Neose Technologies, Inc. Glycopegylated interferon alpha
PT2371856T (pt) * 2004-11-12 2022-08-12 Bayer Healthcare Llc Modificação de fviii direcionada a sítio
WO2006067230A1 (en) 2004-12-23 2006-06-29 Novo Nordisk Health Care Ag Reduction of the content of protein contaminants in compositions comprising a vitamin k-dependent protein of interest
WO2006114105A2 (en) * 2005-04-26 2006-11-02 Maxygen Holdings Ltd. Use of modified factor vii for treating bleeding
EP1888098A2 (en) 2005-05-25 2008-02-20 Neose Technologies, Inc. Glycopegylated erythropoietin formulations
EP1893632B1 (en) 2005-06-17 2015-08-12 Novo Nordisk Health Care AG Selective reduction and derivatization of engineered factor vii proteins comprising at least one non-native cysteine
CA2612646C (en) * 2005-06-24 2015-11-24 Drugrecure Aps Airway administration of tissue factor pathway inhibitor in inflammatory conditions affecting the respiratory tract
US7696318B2 (en) 2005-07-13 2010-04-13 Novo Nordisk Health Care Ag Host cell protein knock-out cells for production of therapeutic proteins
EP1919498A2 (en) * 2005-08-26 2008-05-14 Maxygen Holdings Ltd. Liquid factor vii composition
JP5894722B2 (ja) 2005-09-01 2016-03-30 ノボ ノルディスク ヘルス ケア アーゲー 第ｖｉｉ因子ポリペプチドの疎水性相互作用クロマトグラフィ精製
WO2007039475A1 (en) * 2005-09-21 2007-04-12 Novo Nordisk Health Care Ag Human coagulation factor vii polypeptides
EP1816201A1 (en) * 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
ES2399138T3 (es) * 2006-03-16 2013-03-26 Stellaris Pharmaceuticals Aps Tratamiento local con factor VII
US7645860B2 (en) * 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
US7982010B2 (en) * 2006-03-31 2011-07-19 Baxter International Inc. Factor VIII polymer conjugates
EP2010222A1 (en) 2006-03-31 2009-01-07 Baxter International Inc. Pegylated factor viii
US7985839B2 (en) * 2006-03-31 2011-07-26 Baxter International Inc. Factor VIII polymer conjugates
DE602007009956D1 (de) * 2006-04-07 2010-12-02 Novo Nordisk Healthcare Ag Kovalenter faktor vii-gewebefaktor-komplex
DK2007885T3 (da) * 2006-04-11 2010-11-08 Csl Behring Gmbh Fremgangsmåde til forøgelse af in vivo-genvindingen af terapeutiske polypeptider
CN104593348A (zh) 2006-05-24 2015-05-06 诺沃—诺迪斯克保健股份有限公司 具有延长的体内半寿期的因子ix类似物
FR2901707B1 (fr) 2006-05-31 2017-09-29 Lab Francais Du Fractionnement Composition de facteur vii recombinant ou transgenique, chaque molecule de facteur vii possedant deux sites de n-glycosylation a motifs glycanniques definis
CN101495155A (zh) 2006-07-07 2009-07-29 诺沃-诺迪斯克保健股份有限公司 新的蛋白结合物及其制备方法
WO2008009634A2 (en) * 2006-07-17 2008-01-24 Novo Nordisk Health Care Ag Factor viia analogues with increased activity for treating thrombocytopenia
FR2904558B1 (fr) * 2006-08-01 2008-10-17 Lab Francais Du Fractionnement "composition de facteur vii recombinant ou transgenique, presentant majoritairement des formes glycanniques biantennees, bisialylees et non fucosylees"
ES2531934T3 (es) 2006-09-01 2015-03-20 Novo Nordisk Health Care Ag Glicoproteínas modificadas
US8777971B2 (en) * 2006-10-17 2014-07-15 Amj Bv Device and method for joining vessels in anastomosis
JP5876208B2 (ja) 2006-12-15 2016-03-02 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ 延長されたｉｎｖｉｖｏ半減期を有する第ＶＩＩａ因子−（ポリ）シアル酸結合体
AU2007338298B2 (en) 2006-12-22 2013-02-07 Csl Behring Gmbh Modified coagulation factors with prolonged in vivo half-life
EP1972687A1 (en) * 2007-03-23 2008-09-24 GenOdyssee Polynucleotides and polypeptides of human factor VII gene, SNPs
PT2147096E (pt) * 2007-04-13 2015-07-21 Catalyst Biosciences Inc Polipéptidos do factor vii modificados e suas utilizações
EP2152233A1 (en) 2007-05-02 2010-02-17 Novo Nordisk Health Care AG High concentration factor vii polypeptide formulations comprising an aromatic preservative and an antioxidant
WO2009012502A1 (en) * 2007-07-19 2009-01-22 The Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Arizona State University Self- anchoring mems intrafascicular neural electrode
US8207112B2 (en) 2007-08-29 2012-06-26 Biogenerix Ag Liquid formulation of G-CSF conjugate
AU2008311973B2 (en) * 2007-10-15 2013-10-03 Cangene Corporation Human Factor IX variants with an extended half life
DK2235197T3 (en) 2007-12-27 2017-10-09 Baxalta GmbH Methods of cell culture
TWI465247B (zh) * 2008-04-11 2014-12-21 Catalyst Biosciences Inc 經修飾的因子ｖｉｉ多肽和其用途
EP2444491B1 (en) 2008-04-21 2016-11-16 Novo Nordisk Healthcare Ag Hyperglycosylated human coagulation factor IX
CA2722169A1 (en) * 2008-04-24 2009-10-29 Celtic Pharma Peg Ltd. Factor ix conjugates with extended half-lives
WO2009141433A1 (en) * 2008-05-23 2009-11-26 Novo Nordisk Health Care Ag Low viscosity compositions comprising a pegylated gla-domain containing protein
JP2011520999A (ja) * 2008-05-23 2011-07-21 ノボ ノルディスク ヘルス ケア アーゲー 高濃度の芳香族保存料を有するペグ官能化セリンプロテアーゼの製剤
CN102112157B (zh) 2008-08-06 2013-05-29 诺沃-诺迪斯克保健股份有限公司 具有延长的体内效能的缀合蛋白
CA2747825A1 (en) 2009-01-22 2010-07-29 Novo Nordisk Health Care Ag Stable growth hormone compounds
NZ606427A (en) 2009-02-03 2014-10-31 Amunix Operating Inc Extended recombinant polypeptides and compositions comprising same
JP6227870B2 (ja) 2009-06-09 2017-11-08 プロロング ファーマシューティカルズ，エルエルシー ヘモグロビン組成物
WO2010149172A2 (en) 2009-06-24 2010-12-29 Rigshospitalet SYSTEMIC PRO-HEMOSTATIC EFFECT OF CLOTTING FACTORS IN COMBINATION WITH SYMPATHICOMIMETICS WITH AGONISTIC EFFECTS ON α-ADRENERGIC AND/OR β-ADRENERGIC RECEPTORS OF THE SYMPATHETIC NERVOUS SYSTEM, RELATED TO IMPROVED CLOT STRENGTH.
WO2011012850A2 (en) 2009-07-27 2011-02-03 Lipoxen Technologies Limited Glycopolysialylation of non-blood coagulation proteins
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
NZ623810A (en) 2009-07-27 2015-10-30 Lipoxen Technologies Ltd Glycopolysialylation of non-blood coagulation proteins
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
CN102497884A (zh) * 2009-07-27 2012-06-13 巴克斯特国际公司 凝血蛋白缀合物
JP6086528B2 (ja) 2009-08-06 2017-03-01 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 長期のインビボ有効性を有する成長ホルモン
WO2011018515A1 (en) 2009-08-14 2011-02-17 Novo Nordisk Health Care Ag Method of purifying pegylated proteins
WO2011028228A1 (en) 2009-08-24 2011-03-10 Amunix Operating Inc. Coagulation factor vii compositions and methods of making and using same
US20110150843A1 (en) * 2009-10-30 2011-06-23 National Institute Of Immunology Method for the therapeutic correction of hemophilia a by transplanting bone marrow cells
AU2011208625C1 (en) 2010-01-22 2022-08-18 Novo Nordisk Health Care Ag Growth hormones with prolonged in-vivo efficacy
JP5980689B2 (ja) 2010-01-22 2016-08-31 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 安定な成長ホルモン化合物
GB201007356D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIIa
CA2801223C (en) 2010-06-04 2019-12-03 Sk Chemicals Co., Ltd. Fusion protein having factor vii activity
TWI557135B (zh) 2010-11-03 2016-11-11 介控生化科技公司 經修飾之第九因子多胜肽及其用途
CN108265038A (zh) * 2010-12-03 2018-07-10 基因流股份有限公司 改善的光-发射分子
PT2654794T (pt) 2010-12-22 2020-06-11 Baxalta Inc Materiais e métodos para conjugação de um derivado de ácido gordo solúvel em água a uma proteína
HUE043894T2 (hu) 2011-06-10 2019-09-30 Bioverativ Therapeutics Inc Koagulációt elõsegítõ vegyületek és alkalmazásuk módszerei
CN103974716B (zh) * 2011-10-06 2016-08-24 韩美科学株式会社 凝血因子Ⅶ和Ⅶa衍生物、包括其的缀合物和复合体及其用途
CA2864126A1 (en) 2012-02-15 2013-08-22 Biogen Idec Ma Inc. Recombinant factor viii proteins
ES2935489T3 (es) 2012-02-15 2023-03-07 Bioverativ Therapeutics Inc Composiciones de factor VIII y métodos de preparación y uso de las mismas
EP2906693A1 (en) * 2012-10-15 2015-08-19 Novo Nordisk Health Care AG Coagulation factor vii polypeptides
WO2014060397A1 (en) 2012-10-15 2014-04-24 Novo Nordisk Health Care Ag Factor vii conjugates
CA2896057C (en) 2012-12-24 2023-03-14 Maxine Bauzon Short-acting factor vii polypeptides
WO2014166836A1 (en) 2013-04-05 2014-10-16 Novo Nordisk A/S Growth hormone compound formulation
US10548953B2 (en) 2013-08-14 2020-02-04 Bioverativ Therapeutics Inc. Factor VIII-XTEN fusions and uses thereof
WO2015055692A1 (en) 2013-10-15 2015-04-23 Novo Nordisk Health Care Ag Coagulation factor vii polypeptides
MX2018001497A (es) 2015-08-03 2018-05-15 Bioverativ Therapeutics Inc Proteinas de fusion de factor ix y metodos para producirlas y usarlas.
RU2633588C2 (ru) * 2015-11-03 2017-10-13 Евгений Федорович Чередников Способ эндоскопического лечения язвенного гастродуоденального кровотечения
IL319473A (en) 2016-12-02 2025-05-01 Bioverativ Therapeutics Inc Methods for treating hemophilic arthritis using chimeric blood clotting factors
DK3793588T3 (da) 2018-05-18 2025-06-16 Bioverativ Therapeutics Inc Fremgangsmåder til behandling af hæmofili a
WO2021030787A1 (en) 2019-08-15 2021-02-18 Catalyst Biosciences, Inc. Modified factor vii polypeptides for subcutaneous administration and on-demand treatment
PH12022551163A1 (en) 2019-11-13 2023-09-25 Amunix Pharmaceuticals Inc Barcoded xten polypeptides and compositions thereof, and methods for making and using the same
EP4422650A4 (en) * 2021-10-29 2025-11-05 Sigilon Therapeutics Inc Compositions for cell therapies and associated methods

Family Cites Families (140)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4470461A (en) 1982-09-30 1984-09-11 Phillips Petroleum Company Organic nitro compounds as cosurfactants in enhanced oil recovery processes
US4870008A (en) 1983-08-12 1989-09-26 Chiron Corporation Secretory expression in eukaryotes
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
US4931373A (en) 1984-05-25 1990-06-05 Zymogenetics, Inc. Stable DNA constructs for expression of α-1 antitrypsin
GB8430252D0 (en) 1984-11-30 1985-01-09 Beecham Group Plc Compounds
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
GR860984B (en) 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
ZA862768B (en) * 1985-04-17 1986-12-30 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
JP2524586B2 (ja) 1985-06-26 1996-08-14 シタス コーポレイション ポリマ−接合を利用する医薬組成物用蛋白質の可溶化
EP0208491B1 (en) 1985-07-03 1993-08-25 Genencor International, Inc. Hybrid polypeptides and process for their preparation
US5679543A (en) 1985-08-29 1997-10-21 Genencor International, Inc. DNA sequences, vectors and fusion polypeptides to increase secretion of desired polypeptides from filamentous fungi
JP2523562B2 (ja) 1985-10-25 1996-08-14 ザイモジェネティックス インコーポレーテッド 外来タンパク質を分泌することを目的としたｂａｒ１の使用法
US5180583A (en) 1985-11-26 1993-01-19 Hedner Ulla K E Method for the treatment of bleeding disorders
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
JPS63502716A (ja) 1986-03-07 1988-10-13 マサチューセッツ・インステチュート・オブ・テクノロジー 糖タンパク安定性の強化方法
DK122686D0 (da) 1986-03-17 1986-03-17 Novo Industri As Fremstilling af proteiner
US5258288A (en) 1986-07-25 1993-11-02 Genzyme Corporation Vector containing DNA encoding mature human protein S
DK323587D0 (da) 1987-06-25 1987-06-25 Novo Industri As Protein
JP2799316B2 (ja) 1987-06-12 1998-09-17 ヘキスト・マリオン・ルセル株式会社 雑種ヒトプロテインｃおよびその遺伝子工学的製法
US4904584A (en) 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
US5648254A (en) 1988-01-15 1997-07-15 Zymogenetics, Inc. Co-expression in eukaryotic cells
US4847325A (en) 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
JPH0246296A (ja) 1988-08-09 1990-02-15 Hoechst Japan Ltd 雑種プロテインｃ及びその製造方法
JP2928287B2 (ja) * 1988-09-29 1999-08-03 協和醗酵工業株式会社 新規ポリペプチド
US5218092A (en) * 1988-09-29 1993-06-08 Kyowa Hakko Kogyo Co., Ltd. Modified granulocyte-colony stimulating factor polypeptide with added carbohydrate chains
GB8824591D0 (en) 1988-10-20 1988-11-23 Royal Free Hosp School Med Fractionation process
US5349052A (en) 1988-10-20 1994-09-20 Royal Free Hospital School Of Medicine Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor
WO1990005783A1 (en) 1988-11-18 1990-05-31 Cetus Corporation Insect signal peptide mediated secretion of recombinant proteins
US5041376A (en) 1988-12-09 1991-08-20 The Board Of Regents Of The University Of Texas System Method for identifying or shielding functional sites or epitopes of proteins that enter the exocytotic pathway of eukaryotic cells, the mutant proteins so produced and genes encoding said mutant proteins
US5047335A (en) 1988-12-21 1991-09-10 The Regents Of The University Of Calif. Process for controlling intracellular glycosylation of proteins
JP2989002B2 (ja) 1988-12-22 1999-12-13 キリン―アムジエン・インコーポレーテツド 化学修飾顆粒球コロニー刺激因子
US4902502A (en) 1989-01-23 1990-02-20 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
ATE181732T1 (de) 1989-04-19 1999-07-15 Novo Nordisk As Aktive karbonate von polyalkylenoxyden zur modifizierung von polypeptiden
US5122614A (en) 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
DK0400472T3 (da) 1989-05-27 1996-05-13 Sumitomo Pharma Fremgangsmåde til fremstilling af polyethylenglycolderivater og modificeret protein
US5093317A (en) 1989-06-05 1992-03-03 Cephalon, Inc. Treating disorders by application of insulin-like growth factor
US5077214A (en) 1989-07-07 1991-12-31 The Texas A&M University System Use of baculovirus early promoters for expression of foreign genes in stably transformed insect cells
US4973317A (en) 1989-07-14 1990-11-27 Bobrove Arthur M Automatic sheath protection of hypodermic needle
US5023328A (en) 1989-08-04 1991-06-11 The Texas A&M University System Lepidopteran AKH signal sequence
US5580560A (en) 1989-11-13 1996-12-03 Novo Nordisk A/S Modified factor VII/VIIa
US5225537A (en) 1989-12-29 1993-07-06 Zymogenetics, Inc. Methods for producing hybrid phospholipid-binding proteins
EP0512011B1 (en) 1990-01-26 1994-04-06 IMMUNO Aktiengesellschaft Recombinantly produced blood factors and process for the expression of said blood factors, as well as vaccinia virus recombinants used in said process
EP0521873B1 (en) 1990-01-29 1999-06-02 Zymogenetics, Inc. Anticoagulant proteins
US5219564A (en) 1990-07-06 1993-06-15 Enzon, Inc. Poly(alkylene oxide) amino acid copolymers and drug carriers and charged copolymers based thereon
US5583107A (en) 1990-09-04 1996-12-10 Cor Therapeutics, Inc. Agents affecting thrombosis and hemostasis
US5531916A (en) 1990-10-03 1996-07-02 E. I. Du Pont De Nemours And Company Hydrofluorocarbon cleaning compositions
WO1992008790A1 (en) 1990-11-14 1992-05-29 Cargill, Incorporated Conjugates of poly(vinylsaccharide) with proteins for the stabilization of proteins
ATE158816T1 (de) 1990-11-26 1997-10-15 Genetics Inst Expression von pace in wirtszellen und verfahren zu dessen verwendung
US5861374A (en) * 1991-02-28 1999-01-19 Novo Nordisk A/S Modified Factor VII
US5788965A (en) 1991-02-28 1998-08-04 Novo Nordisk A/S Modified factor VII
WO1994027631A1 (en) 1993-05-21 1994-12-08 Zymogenetics, Inc. Modified factor vii
US5833982A (en) 1991-02-28 1998-11-10 Zymogenetics, Inc. Modified factor VII
US5817788A (en) 1991-02-28 1998-10-06 Zymogenetics, Inc. Modified factor VII
ATE273393T1 (de) 1991-02-28 2004-08-15 Zymogenetics Inc Modifizierter faktor-vii
WO1992016555A1 (en) 1991-03-18 1992-10-01 Enzon, Inc. Hydrazine containing conjugates of polypeptides and glycopolypeptides with polymers
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5504064A (en) 1991-04-10 1996-04-02 Oklahoma Medical Research Foundation Treatment of bleeding with modified tissue factor in combination with an activator of FVII
DE4113487C1 (enExample) 1991-04-25 1992-11-05 Fleischgrosshandel Hans-Werner & Bernd Meixner Gmbh, 6301 Wettenberg, De
US5281698A (en) 1991-07-23 1994-01-25 Cetus Oncology Corporation Preparation of an activated polymer ester for protein conjugation
ZA933926B (en) 1992-06-17 1994-01-03 Amgen Inc Polyoxymethylene-oxyethylene copolymers in conjuction with blomolecules
AU5006993A (en) 1992-08-21 1994-03-15 Enzon, Inc. Novel attachment of polyalkylene oxides to bio-effecting substances
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
NZ250375A (en) 1992-12-09 1995-07-26 Ortho Pharma Corp Peg hydrazone and peg oxime linkage forming reagents and protein derivatives
US5298643A (en) 1992-12-22 1994-03-29 Enzon, Inc. Aryl imidate activated polyalkylene oxides
US5349001A (en) 1993-01-19 1994-09-20 Enzon, Inc. Cyclic imide thione activated polyalkylene oxides
US5321095A (en) 1993-02-02 1994-06-14 Enzon, Inc. Azlactone activated polyalkylene oxides
IL104734A0 (en) 1993-02-15 1993-06-10 Univ Bar Ilan Bioactive conjugates of cellulose with amino compounds
DK38293D0 (da) 1993-03-31 1993-03-31 Novo Nordisk As Fremstilling af proteiner
US5871384A (en) * 1993-04-20 1999-02-16 Kichijo; Hiroshi Block assembly and devices formed thereby
JPH0720127A (ja) 1993-05-07 1995-01-24 Eisai Co Ltd 各種ｐｉｖｋａの測定方法および測定試薬
WO1994028024A1 (en) 1993-06-01 1994-12-08 Enzon, Inc. Carbohydrate-modified polymer conjugates with erythropoietic activity
WO1995000162A1 (en) 1993-06-21 1995-01-05 Enzon, Inc. Site specific synthesis of conjugated peptides
GB9317618D0 (en) 1993-08-24 1993-10-06 Royal Free Hosp School Med Polymer modifications
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5951974A (en) 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
KR960705579A (ko) 1993-11-10 1996-11-08 에릭에스. 딕커 개선된 인터페론 중합체 결합체(Improved interferon polymer conjugates)
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
DE4343591A1 (de) 1993-12-21 1995-06-22 Evotec Biosystems Gmbh Verfahren zum evolutiven Design und Synthese funktionaler Polymere auf der Basis von Formenelementen und Formencodes
US6117679A (en) 1994-02-17 2000-09-12 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5473034A (en) 1994-03-18 1995-12-05 Hyogo Prefectural Government Method for producing protein-synthetic polymer conjugate and said conjugate produced thereby
US5629384A (en) 1994-05-17 1997-05-13 Consiglio Nazionale Delle Ricerche Polymers of N-acryloylmorpholine activated at one end and conjugates with bioactive materials and surfaces
AU2826495A (en) 1994-06-02 1996-01-04 Enzon, Inc. Method of solubilizing substantially water insoluble materials
US5730990A (en) 1994-06-24 1998-03-24 Enzon, Inc. Non-antigenic amine derived polymers and polymer conjugates
WO1996000787A1 (en) 1994-06-30 1996-01-11 Novo Nordisk Biotech, Inc. Non-toxic, non-toxigenic, non-pathogenic fusarium expression system and promoters and terminators for use therein
US5650234A (en) 1994-09-09 1997-07-22 Surface Engineering Technologies, Division Of Innerdyne, Inc. Electrophilic polyethylene oxides for the modification of polysaccharides, polypeptides (proteins) and surfaces
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
DE4437604A1 (de) 1994-10-21 1996-04-25 Basf Ag Konjugate aus einem Poly- oder Oligopeptid und einer niedermolekularen lipophilen Verbindung
WO1996041813A2 (en) 1994-11-09 1996-12-27 Offord Robin E Functionalized polymers for site-specific attachment
US5738846A (en) 1994-11-10 1998-04-14 Enzon, Inc. Interferon polymer conjugates and process for preparing the same
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
AU5893696A (en) 1995-06-07 1996-12-30 Novo Nordisk A/S Modification of polypeptides
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
EP1213350A3 (en) 1995-08-11 2002-12-04 Novozymes A/S Method for preparing polypeptide variants by in vivo recombination
DE19531637A1 (de) 1995-08-28 1997-03-06 Immuno Ag Pharmazeutische Zusammensetzung zur Behandlung von Blutgerinnungsstörugnen, Verfahren zur Herstellung derselben und deren Verwendung
US5747639A (en) 1996-03-06 1998-05-05 Amgen Boulder Inc. Use of hydrophobic interaction chromatography to purify polyethylene glycols
TW517067B (en) 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
RU2199347C2 (ru) 1996-08-02 2003-02-27 Орто-Макнейл Фармасьютикал, Инк. Полипептиды, обладающие единственным ковалентно связанным n-концевым водорастворимым полимером
US5837843A (en) 1996-11-08 1998-11-17 Oklahoma Medical Research Foundation Modified protein C
DE69735597T2 (de) 1996-11-08 2006-12-21 Oklahoma Medical Research Foundation, Oklahoma Verwendung eines modifizierten protein-c
AU5549998A (en) 1997-01-24 1998-08-18 Novo Nordisk A/S Synthetic leader peptide sequences
DE69800640T2 (de) 1997-01-29 2001-07-05 Polymasc Pharmaceuticals Plc, London Pegylationsverfahren
WO1998035026A1 (en) 1997-02-06 1998-08-13 Novo Nordisk A/S Polypeptide-polymer conjugates having added and/or removed attachment groups
EP0979102A4 (en) 1997-04-30 2005-11-23 Enzon Inc DETAILED POLYPEPTIDE MODIFIED BY POLYALKYLENE OXIDE
EP0921131B1 (en) 1997-06-06 2010-05-26 Kyowa Hakko Kirin Co., Ltd. Chemically modified polypeptides
AT407255B (de) 1997-06-20 2001-02-26 Immuno Ag Rekombinanter zellklon mit erhöhter stabilität in serum- und proteinfreiem medium und verfahren zur gewinnung des stabilen zellklons
US6475725B1 (en) 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
ES2297889T3 (es) 1997-07-14 2008-05-01 Bolder Biotechnology, Inc. Derivados de hormona de crecimiento y proteinas relacionadas.
WO1999003498A1 (en) 1997-07-18 1999-01-28 Novo Nordisk A/S USE OF FVIIa OR FVIIai FOR THE TREATMENT OF ADVERSE CONDITIONS RELATED TO THE FVIIa MEDIATED INTRACELLULAR SIGNALLING PATHWAY
US6747003B1 (en) 1997-10-23 2004-06-08 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7247708B2 (en) 1997-10-23 2007-07-24 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6017882A (en) 1997-10-23 2000-01-25 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6693075B1 (en) 1997-10-23 2004-02-17 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US5985263A (en) 1997-12-19 1999-11-16 Enzon, Inc. Substantially pure histidine-linked protein polymer conjugates
US5981709A (en) 1997-12-19 1999-11-09 Enzon, Inc. α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same
CN100335503C (zh) 1998-04-28 2007-09-05 应用研究系统Ars股份公司 多元醇干扰素β偶联物
AT408613B (de) 1998-06-17 2002-01-25 Immuno Ag Pharmazeutisches faktor vii-präparat
DE69936351T2 (de) 1998-10-30 2008-02-21 Novozymes A/S Glykosylierte proteine mit reduzierter allergenität
CA2348938A1 (en) 1998-10-30 2000-05-11 Novozymes A/S Low allergenic protein variants
EP1127154B1 (en) 1998-11-06 2008-09-10 Novo Nordisk Health Care AG Method for the production of fvii
AU3210100A (en) 1999-01-19 2000-08-01 Maxygen, Inc. Methods for making character strings, polynucleotides and polypeptides having desired characteristics
WO2000054787A1 (en) 1999-03-16 2000-09-21 The Children's Hospital Of Philadelphia Enhanced gamma-carboxylation of recombinant vitamin k-dependent clotting factors
US6432826B1 (en) * 1999-11-29 2002-08-13 Applied Materials, Inc. Planarized Cu cleaning for reduced defects
NZ521257A (en) * 2000-02-11 2004-10-29 Maxygen Aps Factor VII or VIIa-like molecules
US7220837B1 (en) * 2000-04-28 2007-05-22 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
WO2001083725A1 (en) 2000-05-03 2001-11-08 Novo Nordisk A/S Human coagulation factor vii variants
US7160540B2 (en) 2000-06-30 2007-01-09 Regents Of The University Of Minnesota Methods for detecting activity of clottings factors
US6423826B1 (en) 2000-06-30 2002-07-23 Regents Of The University Of Minnesota High molecular weight derivatives of vitamin K-dependent polypeptides
US20030211094A1 (en) 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
EP2253703A1 (en) 2000-09-13 2010-11-24 Novo Nordisk Health Care AG Human coagulation factor VII variants
ES2429523T3 (es) 2000-09-13 2013-11-15 Novo Nordisk Health Care Ag Variantes del factor VII de coagulación humana
IL154879A0 (en) 2000-10-02 2003-10-31 Novo Nordisk As Factor vii glycoforms
US7173000B2 (en) 2000-11-09 2007-02-06 The Scripps Research Institute Modified factor VIIa
WO2003093465A1 (en) * 2002-04-30 2003-11-13 Maxygen Holdings Ltd. FACTOR VII OR VIIa POLYPEPTIDE VARIANTS
EP1549677B1 (en) * 2002-09-30 2011-04-13 Bayer HealthCare LLC FVII OR FVIIa VARIANTS HAVING INCREASED CLOTTING ACTIVITY
DK1608745T3 (da) 2003-03-20 2009-06-15 Bayer Healthcare Llc FVII eller FVIIa-Varianter
DK1644504T3 (da) * 2003-06-19 2010-05-25 Bayer Healthcare Llc Faktor VII- eller -VIIA-Gla-domænevarianter

Cited By (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009278980A (ja) * 2000-09-13 2009-12-03 Novo Nordisk Health Care Ag ヒト凝固因子ｖｉｉ変異型
US8716240B2 (en) 2001-10-10 2014-05-06 Novo Nordisk A/S Erythropoietin: remodeling and glycoconjugation of erythropoietin
US8008252B2 (en) 2001-10-10 2011-08-30 Novo Nordisk A/S Factor VII: remodeling and glycoconjugation of Factor VII
US8716239B2 (en) 2001-10-10 2014-05-06 Novo Nordisk A/S Granulocyte colony stimulating factor: remodeling and glycoconjugation G-CSF
JP2006513142A (ja) * 2002-06-21 2006-04-20 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト ペジル化されたｖｉｉ因子糖形体
JP2012095641A (ja) * 2003-03-20 2012-05-24 Bayer Healthcare Llc ＦＶＩＩおよびＦＶＩＩａの変種
US8853161B2 (en) 2003-04-09 2014-10-07 Novo Nordisk A/S Glycopegylation methods and proteins/peptides produced by the methods
US9005625B2 (en) 2003-07-25 2015-04-14 Novo Nordisk A/S Antibody toxin conjugates
US8674074B2 (en) 2003-09-09 2014-03-18 Novo Nordisk Healthcare Ag Coagulation factor VII polypeptides
JP2011167193A (ja) * 2003-09-09 2011-09-01 Novo Nordisk Health Care Ag 凝固因子ｖｉｉポリペプチド
JP4824559B2 (ja) * 2003-09-09 2011-11-30 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 凝固因子ｖｉｉポリペプチド
JP2007504809A (ja) * 2003-09-09 2007-03-08 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 凝固因子ｖｉｉポリペプチド
US8916360B2 (en) 2003-11-24 2014-12-23 Novo Nordisk A/S Glycopegylated erythropoietin
US8791066B2 (en) 2004-07-13 2014-07-29 Novo Nordisk A/S Branched PEG remodeling and glycosylation of glucagon-like peptide-1 [GLP-1]
JP2008507990A (ja) * 2004-08-02 2008-03-21 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト Ｆｖｉｉの抱合体
US9200049B2 (en) 2004-10-29 2015-12-01 Novo Nordisk A/S Remodeling and glycopegylation of fibroblast growth factor (FGF)
US10874714B2 (en) 2004-10-29 2020-12-29 89Bio Ltd. Method of treating fibroblast growth factor 21 (FGF-21) deficiency
US9029331B2 (en) 2005-01-10 2015-05-12 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
US9187546B2 (en) 2005-04-08 2015-11-17 Novo Nordisk A/S Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
US8911967B2 (en) 2005-08-19 2014-12-16 Novo Nordisk A/S One pot desialylation and glycopegylation of therapeutic peptides
JP2009507508A (ja) * 2005-09-14 2009-02-26 ノボ ノルディスク ヘルス ケア アーゲー ヒト凝固第ｖｉｉ因子ポリペプチド
US8841439B2 (en) 2005-11-03 2014-09-23 Novo Nordisk A/S Nucleotide sugar purification using membranes
US9187532B2 (en) 2006-07-21 2015-11-17 Novo Nordisk A/S Glycosylation of peptides via O-linked glycosylation sequences
US8969532B2 (en) 2006-10-03 2015-03-03 Novo Nordisk A/S Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography
JP2010514819A (ja) * 2007-01-03 2010-05-06 ノボ ノルディスク ヘルス ケア アーゲー 凝固第ｖｉｉ因子関連ポリペプチドの皮下投与
US9050304B2 (en) 2007-04-03 2015-06-09 Ratiopharm Gmbh Methods of treatment using glycopegylated G-CSF
US9493499B2 (en) 2007-06-12 2016-11-15 Novo Nordisk A/S Process for the production of purified cytidinemonophosphate-sialic acid-polyalkylene oxide (CMP-SA-PEG) as modified nucleotide sugars via anion exchange chromatography
US9150848B2 (en) 2008-02-27 2015-10-06 Novo Nordisk A/S Conjugated factor VIII molecules
JP2015512927A (ja) * 2012-04-16 2015-04-30 カンタブ バイオファーマシューティカルズ パテンツ リミテッド 最適化された皮下治療薬
JP2018024684A (ja) * 2012-04-16 2018-02-15 カンタブ バイオファーマシューティカルズ パテンツ リミテッド 最適化された皮下治療薬

Also Published As

Publication number Publication date
CA2397347A1 (en) 2001-08-16
EP1257295B1 (en) 2009-04-15
US20060240524A1 (en) 2006-10-26
AU783512B2 (en) 2005-11-03
AU3153501A (en) 2001-08-20
US20060240525A1 (en) 2006-10-26
WO2001058935A2 (en) 2001-08-16
DE60138364D1 (de) 2009-05-28
US20090023635A1 (en) 2009-01-22
US8084591B2 (en) 2011-12-27
US7511024B2 (en) 2009-03-31
EP1982732A3 (en) 2011-06-08
JP2005270110A (ja) 2005-10-06
PT1257295E (pt) 2009-07-16
CA2397347C (en) 2011-07-12
US7427592B2 (en) 2008-09-23
US7442524B2 (en) 2008-10-28
JP4509846B2 (ja) 2010-07-21
NO20023804D0 (no) 2002-08-09
US20030096338A1 (en) 2003-05-22
CY1109614T1 (el) 2014-08-13
US7371543B2 (en) 2008-05-13
ATE428445T1 (de) 2009-05-15
US20070243588A1 (en) 2007-10-18
US20060258585A1 (en) 2006-11-16
IL150692A0 (en) 2003-02-12
US20060019336A1 (en) 2006-01-26
DK1257295T3 (da) 2009-08-10
ES2325877T3 (es) 2009-09-23
NZ521257A (en) 2004-10-29
US7754682B2 (en) 2010-07-13
US7598056B2 (en) 2009-10-06
IL199497A0 (en) 2011-07-31
RU2278123C2 (ru) 2006-06-20
US20060252690A1 (en) 2006-11-09
AU2006200448A1 (en) 2006-03-02
PL204285B1 (pl) 2009-12-31
PL206148B1 (pl) 2010-07-30
EP2319541A1 (en) 2011-05-11
WO2001058935A3 (en) 2001-11-29
CN100488562C (zh) 2009-05-20
RU2002124129A (ru) 2004-03-20
PL362856A1 (en) 2004-11-02
AU2006200448B2 (en) 2009-11-12
US20060252127A1 (en) 2006-11-09
US20120171765A1 (en) 2012-07-05
EP1257295A2 (en) 2002-11-20
IL199497A (en) 2013-08-29
CN1400910A (zh) 2003-03-05
US20060228782A1 (en) 2006-10-12
US20060252689A1 (en) 2006-11-09
US6806063B2 (en) 2004-10-19
US20070142280A1 (en) 2007-06-21
AU2010200296A1 (en) 2010-02-18
NO20023804L (no) 2002-09-25
CA2739933A1 (en) 2001-08-16
US7517974B2 (en) 2009-04-14
US7414022B2 (en) 2008-08-19
EP1982732A2 (en) 2008-10-22

Similar Documents

Publication Publication Date Title
JP4509846B2 (ja) 第ＶＩＩ因子または第ＶＩＩａ因子様分子
CA2502162C (en) Fvii or fviia variants having increased clotting activity
US20060276377A1 (en) Factor VII or VIIa Polypeptide Variants

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20050104

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20050401

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20050405

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20050408

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20050405

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20050902